Format

Send to

Choose Destination
See comment in PubMed Commons below
Cells. 2016 Dec 8;5(4). pii: E44.

Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD).

Author information

1
Department of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, 300 George St., Suite 8100, New Haven, CT 06511, USA. mark.fields@yale.edu.
2
Department of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, 300 George St., Suite 8100, New Haven, CT 06511, USA. huey.cai@yale.edu.
3
Department of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, 300 George St., Suite 8100, New Haven, CT 06511, USA. jie.gong@yale.edu.
4
Department of Ophthalmology and Visual Science, Yale School of Medicine, Yale University, 300 George St., Suite 8100, New Haven, CT 06511, USA. lucian.delpriore@yale.edu.

Abstract

The field of stem cell biology has rapidly evolved in the last few decades. In the area of regenerative medicine, clinical applications using stem cells hold the potential to be a powerful tool in the treatment of a wide variety of diseases, in particular, disorders of the eye. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are promising technologies that can potentially provide an unlimited source of cells for cell replacement therapy in the treatment of retinal degenerative disorders such as age-related macular degeneration (AMD), Stargardt disease, and other disorders. ESCs and iPSCs have been used to generate retinal pigment epithelium (RPE) cells and their functional behavior has been tested in vitro and in vivo in animal models. Additionally, iPSC-derived RPE cells provide an autologous source of cells for therapeutic use, as well as allow for novel approaches in disease modeling and drug development platforms. Clinical trials are currently testing the safety and efficacy of these cells in patients with AMD. In this review, the current status of iPSC disease modeling of AMD is discussed, as well as the challenges and potential of this technology as a viable option for cell replacement therapy in retinal degeneration.

KEYWORDS:

Bruch’s membrane; age-related macular degeneration; disease modeling; induced pluripotent stem cell; retinal pigment epithelium

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Support Center